Cyclacel Dividend Yield vs Capex To Revenue Analysis

CYCC Stock  USD 0.40  0.01  2.56%   
Cyclacel Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cyclacel Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclacel Pharmaceuticals is a good investment. Please check the relationship between Cyclacel Pharmaceuticals Dividend Yield and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.

Dividend Yield vs Capex To Revenue

Dividend Yield vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclacel Pharmaceuticals Dividend Yield account and Capex To Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Cyclacel Pharmaceuticals' Dividend Yield and Capex To Revenue is -0.16. Overlapping area represents the amount of variation of Dividend Yield that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Cyclacel Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cyclacel Pharmaceuticals' Dividend Yield and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Dividend Yield of Cyclacel Pharmaceuticals are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Dividend Yield i.e., Cyclacel Pharmaceuticals' Dividend Yield and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.16
Relationship DirectionNegative 
Relationship StrengthInsignificant

Dividend Yield

Dividend Yield is Cyclacel Pharmaceuticals dividend as a percentage of Cyclacel Pharmaceuticals stock price. Cyclacel Pharmaceuticals dividend yield is a measure of Cyclacel Pharmaceuticals stock productivity, which can be interpreted as interest rate earned on an Cyclacel Pharmaceuticals investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.
Most indicators from Cyclacel Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclacel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.At present, Cyclacel Pharmaceuticals' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.04, whereas Selling General Administrative is forecasted to decline to about 5.9 M.
 2023 2024 (projected)
Discontinued Operations17.1K30.4K
Cost Of Revenue28.8K27.4K

Cyclacel Pharmaceuticals fundamental ratios Correlations

0.570.230.15-0.340.010.020.14-0.060.00.180.13-0.69-0.320.830.09-0.020.940.090.090.12-0.080.00.930.110.09
0.57-0.53-0.72-0.030.72-0.8-0.690.21-0.69-0.52-0.73-0.980.020.92-0.58-0.370.790.27-0.3-0.73-0.03-0.630.82-0.730.02
0.23-0.530.83-0.67-0.930.80.91-0.190.720.690.860.37-0.4-0.190.370.040.050.130.610.84-0.470.6-0.040.86-0.24
0.15-0.720.83-0.24-0.850.970.97-0.410.770.820.990.6-0.36-0.410.780.38-0.15-0.270.431.0-0.060.8-0.210.990.02
-0.34-0.03-0.67-0.240.45-0.16-0.42-0.03-0.19-0.42-0.290.140.47-0.250.160.51-0.36-0.44-0.37-0.270.76-0.23-0.28-0.280.29
0.010.72-0.93-0.850.45-0.88-0.90.21-0.76-0.68-0.87-0.590.350.44-0.47-0.170.21-0.02-0.58-0.860.31-0.680.3-0.880.22
0.02-0.80.80.97-0.16-0.880.93-0.30.840.750.970.69-0.26-0.530.790.46-0.28-0.280.420.970.020.78-0.330.970.04
0.14-0.690.910.97-0.42-0.90.93-0.450.720.850.990.57-0.43-0.380.620.16-0.12-0.160.470.98-0.310.8-0.20.99-0.15
-0.060.21-0.19-0.41-0.030.21-0.3-0.450.22-0.57-0.44-0.240.570.14-0.290.250.020.27-0.04-0.430.28-0.560.09-0.440.22
0.0-0.690.720.77-0.19-0.760.840.720.220.410.750.560.17-0.440.570.58-0.26-0.130.390.760.10.43-0.270.760.09
0.18-0.520.690.82-0.42-0.680.750.85-0.570.410.840.46-0.69-0.270.69-0.09-0.05-0.210.320.84-0.260.96-0.130.83-0.11
0.13-0.730.860.99-0.29-0.870.970.99-0.440.750.840.61-0.38-0.420.730.29-0.16-0.240.451.0-0.160.81-0.231.0-0.07
-0.69-0.980.370.60.14-0.590.690.57-0.240.560.460.610.02-0.970.540.32-0.88-0.310.180.620.070.6-0.910.62-0.01
-0.320.02-0.4-0.360.470.35-0.26-0.430.570.17-0.69-0.380.02-0.15-0.280.42-0.27-0.05-0.28-0.380.38-0.61-0.18-0.370.17
0.830.92-0.19-0.41-0.250.44-0.53-0.380.14-0.44-0.27-0.42-0.97-0.15-0.41-0.30.960.28-0.09-0.43-0.13-0.440.97-0.43-0.01
0.09-0.580.370.780.16-0.470.790.62-0.290.570.690.730.54-0.28-0.410.61-0.23-0.470.190.760.480.74-0.230.720.43
-0.02-0.370.040.380.51-0.170.460.160.250.58-0.090.290.320.42-0.30.61-0.24-0.280.130.330.79-0.01-0.170.30.6
0.940.790.05-0.15-0.360.21-0.28-0.120.02-0.26-0.05-0.16-0.88-0.270.96-0.23-0.240.230.04-0.17-0.19-0.240.99-0.17-0.03
0.090.270.13-0.27-0.44-0.02-0.28-0.160.27-0.13-0.21-0.24-0.31-0.050.28-0.47-0.280.230.58-0.25-0.32-0.290.21-0.24-0.15
0.09-0.30.610.43-0.37-0.580.420.47-0.040.390.320.450.18-0.28-0.090.190.130.040.580.44-0.120.29-0.050.45-0.1
0.12-0.730.841.0-0.27-0.860.970.98-0.430.760.841.00.62-0.38-0.430.760.33-0.17-0.250.44-0.110.82-0.241.0-0.01
-0.08-0.03-0.47-0.060.760.310.02-0.310.280.1-0.26-0.160.070.38-0.130.480.79-0.19-0.32-0.12-0.11-0.12-0.1-0.150.61
0.0-0.630.60.8-0.23-0.680.780.8-0.560.430.960.810.6-0.61-0.440.74-0.01-0.24-0.290.290.82-0.12-0.310.81-0.14
0.930.82-0.04-0.21-0.280.3-0.33-0.20.09-0.27-0.13-0.23-0.91-0.180.97-0.23-0.170.990.21-0.05-0.24-0.1-0.31-0.240.05
0.11-0.730.860.99-0.28-0.880.970.99-0.440.760.831.00.62-0.37-0.430.720.3-0.17-0.240.451.0-0.150.81-0.24-0.08
0.090.02-0.240.020.290.220.04-0.150.220.09-0.11-0.07-0.010.17-0.010.430.6-0.03-0.15-0.1-0.010.61-0.140.05-0.08
Click cells to compare fundamentals

Cyclacel Pharmaceuticals Account Relationship Matchups

Cyclacel Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets15.3M36.8M42.6M27.5M8.8M8.4M
Total Stockholder Equity11.7M33.3M37.3M15.5M607K576.7K
Retained Earnings(357.6M)(366.1M)(385.0M)(406.2M)(428.3M)(406.9M)
Common Stock Shares Outstanding54.4K242.2K595.1K657.6K850.8K893.4K
Liabilities And Stockholders Equity15.3M36.8M42.6M27.5M8.8M8.4M
Other Stockholder Equity370.1M400.1M423.0M414.0M429.8M284.3M
Total Liab3.6M3.5M5.3M12.0M8.2M14.1M
Other Current Liab1.5M2.0M3.2M4.8M4.6M3.4M
Total Current Liabilities2.4M2.5M5.3M7.4M8.2M5.8M
Property Plant And Equipment Net1.3M1.3M94K174K102K96.9K
Net Debt(10.7M)(32.3M)(36.5M)(18.2M)(3.3M)(3.5M)
Accounts Payable890K514K2.1M2.6M3.5M2.2M
Cash11.9M33.4M36.6M18.3M3.4M3.2M
Non Current Assets Total1.3M1.3M1.6M3.1M1.4M1.7M
Non Currrent Assets Other(1.3M)(1.3M)1.6M2.9M1.3M1.3M
Cash And Short Term Investments11.9M33.4M36.6M18.3M3.4M3.2M
Non Current Liabilities Total1.2M1.1M30K4.6M37K35.2K
Other Current Assets103K750K4.4M6.1M4.1M4.3M
Property Plant And Equipment Gross1.3M1.3M94K174K522K839.0K
Total Current Assets14.0M35.5M40.9M24.4M7.4M7.1M
Accumulated Other Comprehensive Income(819K)(746K)(748K)(1.3M)(908K)(953.4K)
Common Stock17K6K10K4.5M1K950.0
Net Receivables1.3M1.3M3.7M5.6M2.9M2.7M
Inventory703K684K577K(5.6M)(5.1M)(4.8M)
Property Plant Equipment27K106K94K174K156.6K148.8K
Retained Earnings Total Equity(342.5M)(349.8M)(357.6M)(366.1M)(329.5M)(345.9M)
Net Tangible Assets11.7M33.3M37.3M15.5M17.8M23.9M
Capital Surpluse365.1M365.8M370.1M400.1M460.1M394.6M
Non Current Liabilities Other124K100K1.2M1.1M1.2M1.3M
Net Invested Capital11.7M33.3M37.3M20.0M607K576.7K
Net Working Capital11.6M33.0M35.6M17.0M(717K)(681.2K)
Capital Stock17K6K10K4.5M1K950.0

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(27.40)
Revenue Per Share
0.044
Quarterly Revenue Growth
(0.99)
Return On Assets
(1.03)
Return On Equity
(5.71)
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.